BRCA1 and metastatic prostate carcinoma: For those with high-risk or metastatic prostate cancer, one guideline recommends germline testing only after somatic testing or after a validated prediction tool (e.g., CanRisk) confirms a ≥ 10% probability of detecting BRCA1/2 pathogenic variant [38], whereas many guidelines and consensus statements recommend germline testing across a range of genes for all men diagnosed with metastatic prostate cancer [16, 21–23, 30–37, 41, 43, 45, 48].